Description: Engineering For New Heights in the Treatment of Inflammatory Bowel Disease
ulcerative colitis (143) ibd (138) monoclonal antibodies (58) inflammatory bowel disease (54) mabs (32) crohn’s disease (31) α4β7 (26) tl1a (26) il-23 (26) uc/cd (26)
Aeglea Acquires Spyre Therapeutics
Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.